Objective: To characterize the comprehensive treatment of retinoblastoma (RB) and investigate the related clinical factors. Methods: In this retrospective study, clinical datas were analyzed for 65 cases (92 eyes)of childhood RB that received comprehensive treatment, including chemotherapy, local treatment Oaser or
cryotherapy), and enucleation. Using t-test and Fisher's exact test to analyze the data. Results: The survival rate for the 65 cases was 92%. The eyeballs were preserved in 51% of the children. The rate of eyeball preservation in stage E group was significantly lower than the other four stage groups (P<O.OI). Children
in stage D group (18 cases) and stage E group (24 cases) were treated with chemotherapy combined with local therapy. The eyeballs were preserved in 11 cases in stage D groups and 4 cases in stage E groups.There were no significant differences in the clinical factors between eyeballs preserved or not children.
The patients in stage D and E groups were further divided into three groups according to the location of the tumors in the eye: it showed peripheral retina (including the mid- peripheral retina) group with higher rate of eyeball preservation than the posterior pole retina and the posterior pole retina+peripheral retina group(P=0.009, 0.021). Four of the 42 patients died, all with tumors located in the posterior pole retina (P=0.045 compared to the peripheral retina and to the posterior pole retina+peripheral retina). Conclusions: Compr-ehensive treatment improved the survival and eyeball preservation rate of children with RB. The survival
rates and eyeball preservation rates were closely related to the clinical stage.
路璐,唐松,郭慧,刘桂琴,赵东升. 视网膜母细胞瘤综合治疗的预后及其相关因素[J]. 中华眼视光学与视觉科学杂志, 2017, 19(9): 560-564.
Lu Lu,Song Tang,Hui Guo,Guiqin Liu,Dongsheng Zhao. Analysis of Prognostic Factors of Comprehensive Treatment on Retinoblastoma. Chinese Journal of Optometry Ophthalmology and Visual science, 2017, 19(9): 560-564. DOI: 10.3760/cma.j.issn.1674-845X.2017.09.008
Shields JA. Shields CL, Meadows AT. Chemoreduction in the management of retinoblastoma. Am J Ophthalmol, 2005, 140(3):
50
5-506. DOI: 10 .1016/j. ajo .2005 .04.047.
[11]
Friedman DL, Himelstein B. Shields CL. et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol. 2000, 18(1): 12-17. DOI: 10.1200/JC0.2000.18.1.12.
[12]
Kingston JE, Hungerford JL, Madreperla SA, et al. Results of combined chemotherapy and radiotherapy for advanced
Abramson DH, Lawrence SD, Beaverson KL, et al. Systemic carboplatin for retinoblastoma: change in tumour size over time,Br J Ophthalmol, 2005, 89(12): 1616-1619. DOl: 10.1136/bjo.2005.072033.
[14]
Shields CL. Shields JA, Needle M, et al. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma, Ophthalmology, 1997, 104(12) : 2101-2111 .
[15]
Wilson MW, Rodriguez-Galindo C, Haik BG, et al. Multiagent chemotherapy as neoadjuvant treatment for multifocal
Shields CL. Mashayekhi A, Au AK. et al.The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology, 2006, 113(12): 2276-2280. DOI: 10.1016/j.ophtha.2006.06.018.